Changchun High & New Technology Industries Group Inc, 7.8464%
Walvax BioTech, 6.2229%
Shanghai RAAS Blood Products Co Ltd Class A, 5.1649%
Description
The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China"s biotechnology industry. It is non-diversified.